Abstract
Inhibitors of the IIB-IIIA integrin are widely used to prevent stent thrombosis. Abciximab has been shown to attenuate the inflammatory response in patients undergoing PCI. Herein, we tested the effect of eptifibatide infused during PCI on peripheral lymphocyte activation and CRP levels before, and one month after the procedure showing no noticeable effect. These results may explain the differences in clinical outcome following PCI by use of different IIB-IIIA agents.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Aged
-
Aged, 80 and over
-
Angina, Unstable / blood*
-
Angina, Unstable / therapy
-
Angioplasty, Balloon, Coronary*
-
C-Reactive Protein / drug effects*
-
C-Reactive Protein / metabolism
-
CD4-CD8 Ratio
-
Eptifibatide
-
Female
-
Follow-Up Studies
-
HLA-DR Antigens / blood
-
HLA-DR Antigens / drug effects
-
Humans
-
Lymphocyte Activation / drug effects*
-
Male
-
Middle Aged
-
Peptides / pharmacology*
-
Platelet Aggregation Inhibitors / pharmacology*
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
-
Stents
-
Time Factors
Substances
-
HLA-DR Antigens
-
Peptides
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
C-Reactive Protein
-
Eptifibatide